Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
24 Junio 2021 - 8:42AM
InvestorsHub NewsWire
TORONTO, Canada -- June 24, 2021 -- InvestorsHub
NewsWire -- Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the
"Company"), a biotechnology company focused on
progressing psychedelic therapeutics, today announced the addition
of Dr. Thomas Laughren, to the Clinical Advisory Board. Dr. Thomas
Laughren formerly served as the Director for the Division of
Psychiatry Products, Center for Drug Evaluation and Research at the
FDA where he served for 29 years.
As the former Director for the Division of Psychiatry Products,
Dr. Laughren was responsible for overseeing the review of all
psychiatric drug development activities conducted under INDs
(Investigational New Drug) and the review of all NDAs (New Drug
Applications) and supplements for new psychiatric drug claims. Dr.
Laughren has attained numerous awards for his regulatory
accomplishments.
Dr. Thomas Laughren will be joining recent additions, Maurizio
Fava, MD, Psychiatrist-In-Chief in the Department of Psychiatry at
Massachusetts General Hospital, Tony Back, MD, Professor in the
Department of Medicine and Division of Oncology at the University
of Washington, and Lynn Marie Morski, MD, Esq., President of the
Psychedelic Medicine Association. The Board will be chaired by Alex
Belser, PhD, Cybin's Chief Clinical Officer.
Dr. Alex Belser said, "As we study psychedelic medicines, the
regulatory pathway ahead is still coming into focus. There are
outstanding questions to be addressed as to how psychedelic
treatments may be considered for approval in therapeutic contexts.
Dr. Laughren is familiar with these potential challenges, and he
brings extensive psychiatric regulatory and development expertise.
We are excited to welcome Dr. Laughren to Cybin's Clinical Advisory
Board to provide guidance as we develop our regulatory
strategies."
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this news release related to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "may", "should", "could", "intend",
"estimate", "plan", "anticipate", "expect", "believe" or
"continue", or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding enhanced liquidity, the value of additional capital
markets exposure, access to institutional and retail investors, the
Company's new strategic brand messaging campaign, and psychedelic
drug development programs to potentially treat mental health
disorders. There are numerous risks and uncertainties that could
cause actual results and Cybin's plans and objectives to differ
materially from those expressed in the forward-looking information.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products have not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investors:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (NEO:CYBN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cybin (NEO:CYBN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024